US 11,944,638 B2
Ophthalmic solutions
Vicki Barniak, Fairport, NY (US); Catherine Scheuer, West Henrietta, NY (US); William T. Reindel, Webster, NY (US); John Michael Duex, Livonia, NY (US); and Andrea E. Siverling, Rochester, NY (US)
Assigned to Bausch + Lomb Ireland Limited, (IE)
Filed by Bausch + Lomb Ireland Limited, Dublin (IE)
Filed on Mar. 10, 2022, as Appl. No. 17/691,265.
Claims priority of provisional application 63/159,097, filed on Mar. 10, 2021.
Prior Publication US 2022/0288107 A1, Sep. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/728 (2006.01); A01N 33/12 (2006.01); A01N 37/52 (2006.01); A01P 1/00 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61L 12/14 (2006.01); A61P 27/04 (2006.01); C11D 1/66 (2006.01); C11D 1/722 (2006.01); C11D 3/00 (2006.01); C11D 3/04 (2006.01); C11D 3/20 (2006.01); C11D 3/22 (2006.01); C11D 3/48 (2006.01)
CPC A61K 31/728 (2013.01) [A01N 33/12 (2013.01); A01N 37/52 (2013.01); A01P 1/00 (2021.08); A61K 9/0048 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61L 12/142 (2013.01); A61L 12/145 (2013.01); A61P 27/04 (2018.01); C11D 1/66 (2013.01); C11D 1/722 (2013.01); C11D 3/0078 (2013.01); C11D 3/046 (2013.01); C11D 3/2065 (2013.01); C11D 3/222 (2013.01); C11D 3/227 (2013.01); C11D 3/48 (2013.01)] 21 Claims
 
1. An ophthalmically compatible solution, consisting of:
(a) about 0.005 to about 2 wt. %, based on the total weight of the ophthalmically compatible solution, of hyaluronic acid or a salt thereof;
(b) about 0.01 to about 1 wt. %, based on the total weight of the ophthalmically compatible solution, of erythritol;
(c) sodium chloride, potassium chloride or any combination thereof;
(d) one or more buffers;
(e) glycerol; and
(f) water;
wherein the ophthalmically compatible solution is preservative-free.